A First-In-Human, Open-Label, Multicenter Study of VOR33 in Patients with Acute Myeloid Leukemia who are at High-Risk for Leukemia Relapse following Hematopoietic Cell Transplantation
Contact:
NCT Number:
Protocol:
AAAU4826
Study Status:
Active/Enrolling
Population:
Adult
Phase:
I/II
You are being asked to take part in this study because you have acute myeloid leukemia (AML). Vor Biopharma, is a company that is testing a possible new treatment for AML. This possible new treatment, is VOR33. In this study, your blood-forming stem cells will be genetically modified to become VOR33. VOR33 has not been approved by the Food and Drug Administration (FDA). This is a first time VOR33 is being studied in humans. The sponsor of this study is looking to find out if VOR33 is safe.
Are you Eligible? (Inclusion Criteria)
- Must be between 18 to 70 years old - Have a confirmed diagnosis of AML - The AML must have evidence of CD33 expression
Specialty Area(s)
Blood and Marrow Stem Cell Transplantation, Acute Myeloid Leukemia, Immunotherapy
Principal Investigator
Trial Location(s)
CUIMC/Herbert Irving Pavilion
161 Fort Washington Avenue
New York, NY 10032